Logo image of CBUS

CIBUS INC (CBUS) Stock Fundamental Analysis

NASDAQ:CBUS - Nasdaq - US17166A1016 - Common Stock - Currency: USD

1.88  -0.17 (-8.29%)

Fundamental Rating

2

Taking everything into account, CBUS scores 2 out of 10 in our fundamental rating. CBUS was compared to 571 industry peers in the Biotechnology industry. Both the profitability and financial health of CBUS have multiple concerns. CBUS is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CBUS has reported negative net income.
CBUS had a negative operating cash flow in the past year.
CBUS had negative earnings in each of the past 5 years.
CBUS had a negative operating cash flow in each of the past 5 years.
CBUS Yearly Net Income VS EBIT VS OCF VS FCFCBUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M -250M

1.2 Ratios

CBUS has a worse Return On Assets (-121.07%) than 80.18% of its industry peers.
CBUS's Return On Equity of -411.87% is on the low side compared to the rest of the industry. CBUS is outperformed by 78.04% of its industry peers.
Industry RankSector Rank
ROA -121.07%
ROE -411.87%
ROIC N/A
ROA(3y)-67.69%
ROA(5y)-63.77%
ROE(3y)-177.62%
ROE(5y)-143.55%
ROIC(3y)N/A
ROIC(5y)N/A
CBUS Yearly ROA, ROE, ROICCBUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

CBUS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CBUS Yearly Profit, Operating, Gross MarginsCBUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K

More info and screens

2

2. Health

2.1 Basic Checks

CBUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
CBUS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CBUS has been increased compared to 5 years ago.
Compared to 1 year ago, CBUS has an improved debt to assets ratio.
CBUS Yearly Shares OutstandingCBUS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
CBUS Yearly Total Debt VS Total AssetsCBUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

CBUS has an Altman-Z score of -3.20. This is a bad value and indicates that CBUS is not financially healthy and even has some risk of bankruptcy.
CBUS has a Altman-Z score (-3.20) which is in line with its industry peers.
A Debt/Equity ratio of 0.00 indicates that CBUS is not too dependend on debt financing.
The Debt to Equity ratio of CBUS (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.2
ROIC/WACCN/A
WACC9.39%
CBUS Yearly LT Debt VS Equity VS FCFCBUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

A Current Ratio of 1.44 indicates that CBUS should not have too much problems paying its short term obligations.
CBUS has a Current ratio of 1.44. This is amonst the worse of the industry: CBUS underperforms 82.86% of its industry peers.
A Quick Ratio of 1.44 indicates that CBUS should not have too much problems paying its short term obligations.
The Quick ratio of CBUS (1.44) is worse than 81.96% of its industry peers.
Industry RankSector Rank
Current Ratio 1.44
Quick Ratio 1.44
CBUS Yearly Current Assets VS Current LiabilitesCBUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for CBUS have decreased strongly by -12.99% in the last year.
CBUS shows a strong growth in Revenue. In the last year, the Revenue has grown by 446.45%.
Measured over the past years, CBUS shows a very strong growth in Revenue. The Revenue has been growing by 49.91% on average per year.
EPS 1Y (TTM)-12.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.77%
Revenue 1Y (TTM)446.45%
Revenue growth 3Y-57.61%
Revenue growth 5Y49.91%
Sales Q2Q%250.95%

3.2 Future

The Earnings Per Share is expected to grow by 14.73% on average over the next years. This is quite good.
CBUS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 170.47% yearly.
EPS Next Y60.45%
EPS Next 2Y37.37%
EPS Next 3Y24.04%
EPS Next 5Y14.73%
Revenue Next Year267.86%
Revenue Next 2Y169.86%
Revenue Next 3Y191.67%
Revenue Next 5Y170.47%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CBUS Yearly Revenue VS EstimatesCBUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
CBUS Yearly EPS VS EstimatesCBUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CBUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CBUS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CBUS Price Earnings VS Forward Price EarningsCBUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CBUS Per share dataCBUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

CBUS's earnings are expected to grow with 24.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.37%
EPS Next 3Y24.04%

More info and screens

0

5. Dividend

5.1 Amount

CBUS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CIBUS INC

NASDAQ:CBUS (3/3/2025, 8:17:34 PM)

1.88

-0.17 (-8.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-20 2025-03-20/amc
Inst Owners30.15%
Inst Owner Change6.67%
Ins Owners18.88%
Ins Owner Change3.43%
Market Cap63.69M
Analysts80
Price Target17.98 (856.38%)
Short Float %9.19%
Short Ratio12.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)34.3%
Min EPS beat(2)-37.98%
Max EPS beat(2)106.57%
EPS beat(4)1
Avg EPS beat(4)-175.82%
Min EPS beat(4)-763.16%
Max EPS beat(4)106.57%
EPS beat(8)2
Avg EPS beat(8)-208.1%
EPS beat(12)6
Avg EPS beat(12)-126.77%
EPS beat(16)7
Avg EPS beat(16)-101.43%
Revenue beat(2)2
Avg Revenue beat(2)127.1%
Min Revenue beat(2)86.72%
Max Revenue beat(2)167.48%
Revenue beat(4)4
Avg Revenue beat(4)117.68%
Min Revenue beat(4)35.27%
Max Revenue beat(4)181.24%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.84%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.72%
EPS NY rev (1m)0%
EPS NY rev (3m)-54.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)79.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)16.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.34
P/FCF N/A
P/OCF N/A
P/B 0.59
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-14.79
EYN/A
EPS(NY)-2.56
Fwd EYN/A
FCF(TTM)-1.84
FCFYN/A
OCF(TTM)-1.8
OCFYN/A
SpS0.12
BVpS3.19
TBVpS-5.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -121.07%
ROE -411.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-67.69%
ROA(5y)-63.77%
ROE(3y)-177.62%
ROE(5y)-143.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.13%
Cap/Sales 28.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.44
Quick Ratio 1.44
Altman-Z -3.2
F-Score4
WACC9.39%
ROIC/WACCN/A
Cap/Depr(3y)70.93%
Cap/Depr(5y)98.6%
Cap/Sales(3y)396.58%
Cap/Sales(5y)247.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.77%
EPS Next Y60.45%
EPS Next 2Y37.37%
EPS Next 3Y24.04%
EPS Next 5Y14.73%
Revenue 1Y (TTM)446.45%
Revenue growth 3Y-57.61%
Revenue growth 5Y49.91%
Sales Q2Q%250.95%
Revenue Next Year267.86%
Revenue Next 2Y169.86%
Revenue Next 3Y191.67%
Revenue Next 5Y170.47%
EBIT growth 1Y-49.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-209.86%
EBIT Next 3Y15.81%
EBIT Next 5Y24.55%
FCF growth 1Y-191.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-209.05%
OCF growth 3YN/A
OCF growth 5YN/A